Kurt A. Gustafson Sells 7,255 Shares of OmniAb, Inc. (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) CFO Kurt A. Gustafson sold 7,255 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $3.67, for a total value of $26,625.85. Following the transaction, the chief financial officer now directly owns 206,211 shares in the company, valued at approximately $756,794.37. This represents a 3.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

OmniAb Trading Down 5.9 %

Shares of NASDAQ OABI opened at $3.65 on Friday. OmniAb, Inc. has a 12-month low of $3.10 and a 12-month high of $6.55. The company has a market cap of $515.45 million, a P/E ratio of -5.89 and a beta of -0.12. The stock has a fifty day moving average price of $3.48 and a 200 day moving average price of $3.90.

Wall Street Analysts Forecast Growth

OABI has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of OmniAb in a research report on Thursday, November 14th. Benchmark reaffirmed a “buy” rating and issued a $8.00 target price on shares of OmniAb in a research report on Thursday, November 14th.

Institutional Trading of OmniAb

Large investors have recently added to or reduced their stakes in the stock. Barclays PLC increased its holdings in OmniAb by 321.5% in the 3rd quarter. Barclays PLC now owns 143,215 shares of the company’s stock valued at $606,000 after purchasing an additional 109,236 shares in the last quarter. FMR LLC grew its stake in shares of OmniAb by 10.6% during the third quarter. FMR LLC now owns 138,813 shares of the company’s stock valued at $587,000 after acquiring an additional 13,324 shares in the last quarter. Atria Investments Inc acquired a new stake in shares of OmniAb during the third quarter valued at about $148,000. Murchinson Ltd. acquired a new stake in shares of OmniAb during the third quarter valued at about $4,230,000. Finally, State Street Corp grew its stake in shares of OmniAb by 1.7% during the third quarter. State Street Corp now owns 2,031,676 shares of the company’s stock valued at $8,594,000 after acquiring an additional 34,654 shares in the last quarter. 72.08% of the stock is currently owned by institutional investors and hedge funds.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.